APLT
Applied Therapeutics, Inc.
Price Chart
No historical data available
Latest Quote
$0.10
Current Price| Open | $0.10 |
| Day High | $0.11 |
| Day Low | $0.10 |
| Volume | 2,690,459 |
Stock Information
| Shares Outstanding | 144.30M |
| Total Debt | $2.50M |
| Cash Equivalents | $11.95M |
| Revenue | $1.00M |
| Net Income | $-18.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.86M |
| EPS (TTM) | $-0.10 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.
đ° Latest News
BC-Most Active Stocks
Associated Press Finance âĸ 2025-12-24T15:30:18ZHere's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now
Zacks âĸ 2025-12-16T14:55:01Z
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why
Zacks âĸ 2025-11-27T17:00:04Z
Can Changes in Leadership and FDA Dialogue Reshape Applied Therapeuticsâ (APLT) Path in Rare Diseases?
Simply Wall St. âĸ 2025-11-15T00:19:05Z
Institutional investors may adopt severe steps after Applied Therapeutics, Inc.'s (NASDAQ:APLT) latest 19% drop adds to a year losses
Simply Wall St. âĸ 2025-10-04T13:46:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $455,000 | $9,993,000 | $0 | $0 |
| Operating Revenue | $455,000 | $9,993,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $104,754,000 | $74,528,000 | $82,950,000 | $105,618,000 |
| Other Income Expense | $-4,859,000 | $-56,600,000 | $-243,000 | $-521,000 |
| Other Non Operating Income Expenses | $-77,000 | $-27,000 | $-177,000 | $-521,000 |
| Net Non Operating Interest Income Expense | $3,534,000 | $1,372,000 | $685,000 | $555,000 |
| Operating Expense | $104,754,000 | $74,528,000 | $82,950,000 | $105,618,000 |
| General And Administrative Expense | $56,010,000 | $20,623,000 | $27,316,000 | $43,048,000 |
| Total Other Finance Cost | - | - | $-685,000 | $-555,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Net Interest Income | $3,534,000 | $1,372,000 | $685,000 | $555,000 |
| Interest Income | $3,534,000 | $1,372,000 | $685,000 | - |
| Normalized Income | $-100,842,000 | $-63,190,000 | $-82,442,000 | $-105,584,000 |
| Net Income From Continuing And Discontinued Operation | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Total Operating Income As Reported | $-104,299,000 | $-64,535,000 | $-82,950,000 | $-105,618,000 |
| Net Income Common Stockholders | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Net Income | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Net Income Including Noncontrolling Interests | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Net Income Continuous Operations | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Pretax Income | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Interest Income Non Operating | $3,534,000 | $1,372,000 | $685,000 | - |
| Operating Income | $-104,299,000 | $-64,535,000 | $-82,950,000 | $-105,618,000 |
| Per Share | ||||
| Diluted EPS | $-0.76 | $-1.42 | $-2.18 | $-4.12 |
| Basic EPS | $-0.76 | $-1.42 | $-2.18 | $-4.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-99,091,000 | $-7,608,000 | $-82,441,000 | $-105,203,000 |
| Total Unusual Items | $-4,782,000 | $-56,573,000 | $-66,000 | - |
| Total Unusual Items Excluding Goodwill | $-4,782,000 | $-56,573,000 | $-66,000 | - |
| Reconciled Depreciation | $426,000 | $354,000 | $443,000 | $415,000 |
| EBITDA (Bullshit earnings) | $-103,873,000 | $-64,181,000 | $-82,507,000 | $-105,203,000 |
| EBIT | $-104,299,000 | $-64,535,000 | $-82,950,000 | $-105,618,000 |
| Diluted Average Shares | $139,534,746 | $84,244,494 | $37,825,431 | $25,598,181 |
| Basic Average Shares | $139,534,746 | $84,244,494 | $37,825,431 | $25,598,181 |
| Diluted NI Availto Com Stockholders | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Gain On Sale Of Security | $-4,782,000 | $-56,573,000 | $-66,000 | - |
| Research And Development | $48,744,000 | $53,905,000 | $55,634,000 | $62,570,000 |
| Selling General And Administration | $56,010,000 | $20,623,000 | $27,316,000 | $43,048,000 |
| Other Gand A | $37,895,000 | $10,280,000 | $12,554,000 | $23,614,000 |
| Insurance And Claims | $1,503,000 | $2,274,000 | $3,682,000 | $4,399,000 |
| Salaries And Wages | $16,612,000 | $8,069,000 | $11,080,000 | $15,035,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Total Assets | $86,691,000 | $54,833,000 | $38,363,000 | $89,892,000 |
| Total Non Current Assets | $3,045,000 | $447,000 | $1,055,000 | $1,498,000 |
| Non Current Prepaid Assets | $253,000 | $0 | - | - |
| Current Assets | $83,646,000 | $54,386,000 | $37,308,000 | $88,394,000 |
| Other Current Assets | $461,000 | $998,000 | $1,748,000 | $2,087,000 |
| Prepaid Assets | $3,787,000 | $3,490,000 | $4,705,000 | $4,959,000 |
| Cash Cash Equivalents And Short Term Investments | $79,398,000 | $49,898,000 | $30,580,000 | $80,823,000 |
| Cash And Cash Equivalents | $79,398,000 | $49,898,000 | $16,657,000 | $53,888,000 |
| Cash Equivalents | $73,233,000 | $25,011,000 | $15,320,000 | $41,217,000 |
| Cash Financial | $6,165,000 | $24,887,000 | $1,337,000 | $12,671,000 |
| Receivables | - | $285,000 | $275,000 | $525,000 |
| Taxes Receivable | - | $262,000 | $252,000 | $502,000 |
| Accrued Interest Receivable | - | $23,000 | $23,000 | $23,000 |
| Debt | ||||
| Total Debt | $2,795,000 | $777,000 | $1,513,000 | $2,122,000 |
| Long Term Debt And Capital Lease Obligation | $2,389,000 | $38,000 | $414,000 | $891,000 |
| Current Debt And Capital Lease Obligation | $406,000 | $739,000 | $1,099,000 | $1,231,000 |
| Current Debt | - | $310,000 | $622,000 | $789,000 |
| Long Term Debt | - | - | $464,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,685,000 | $71,979,000 | $34,302,000 | $27,353,000 |
| Total Non Current Liabilities Net Minority Interest | $2,389,000 | $797,000 | $878,000 | $891,000 |
| Current Liabilities | $27,296,000 | $71,182,000 | $33,424,000 | $26,462,000 |
| Other Current Liabilities | $6,917,000 | $54,104,000 | $14,138,000 | $987,000 |
| Current Deferred Liabilities | $212,000 | $667,000 | $0 | - |
| Current Notes Payable | $0 | $310,000 | $622,000 | $789,000 |
| Payables And Accrued Expenses | $15,744,000 | $13,606,000 | $15,886,000 | $21,465,000 |
| Payables | $4,433,000 | $1,742,000 | $4,534,000 | $9,461,000 |
| Accounts Payable | $4,433,000 | $1,742,000 | $4,534,000 | $9,461,000 |
| Other Non Current Liabilities | - | $759,000 | $464,000 | - |
| Equity | ||||
| Common Stock Equity | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Total Equity Gross Minority Interest | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Stockholders Equity | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Retained Earnings | $-574,210,000 | $-468,586,000 | $-348,823,000 | $-266,315,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $51,000 | $-107,000 |
| Other Equity Adjustments | - | - | $51,000 | $-107,000 |
| Other | ||||
| Ordinary Shares Number | $137,228,741 | $84,869,832 | $48,063,358 | $26,215,514 |
| Share Issued | $137,228,741 | $84,869,832 | $48,063,358 | $26,215,514 |
| Tangible Book Value | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Invested Capital | $57,006,000 | $-16,836,000 | $4,683,000 | $63,328,000 |
| Working Capital | $56,350,000 | $-16,796,000 | $3,884,000 | $61,932,000 |
| Capital Lease Obligations | $2,795,000 | $467,000 | $891,000 | $1,333,000 |
| Total Capitalization | $57,006,000 | $-17,146,000 | $4,061,000 | $62,539,000 |
| Additional Paid In Capital | $631,181,000 | $451,432,000 | $352,828,000 | $328,958,000 |
| Capital Stock | $35,000 | $8,000 | $5,000 | $3,000 |
| Common Stock | $35,000 | $8,000 | $5,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,389,000 | $38,000 | $414,000 | $891,000 |
| Current Deferred Revenue | $212,000 | $667,000 | $0 | - |
| Current Capital Lease Obligation | $406,000 | $429,000 | $477,000 | $442,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,017,000 | $2,066,000 | $2,301,000 | $2,779,000 |
| Current Accrued Expenses | $11,311,000 | $11,864,000 | $11,352,000 | $12,004,000 |
| Net PPE | $2,792,000 | $447,000 | $1,055,000 | $1,498,000 |
| Gross PPE | $2,792,000 | $447,000 | $1,055,000 | $1,498,000 |
| Other Properties | $2,792,000 | $447,000 | $857,000 | $1,298,000 |
| Treasury Shares Number | - | $0 | - | - |
| Leases | - | $0 | $198,000 | $200,000 |
| Properties | - | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $13,923,000 | $26,935,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-84,305,000 | $-55,173,000 | $-78,093,000 | $-90,728,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-84,305,000 | $-55,173,000 | $-78,093,000 | $-90,728,000 |
| Cash Flow From Continuing Operating Activities | $-84,305,000 | $-55,173,000 | $-78,093,000 | $-90,728,000 |
| Operating Gains Losses | $4,782,000 | $56,573,000 | $66,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $13,872,000 | $13,170,000 | $12,433,000 |
| Cash Flow From Continuing Investing Activities | $0 | $13,872,000 | $13,170,000 | $12,433,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $104,748,000 | $64,514,000 | $27,811,000 | $74,421,000 |
| Financing Cash Flow | $113,805,000 | $74,542,000 | $27,692,000 | $74,717,000 |
| Cash Flow From Continuing Financing Activities | $113,805,000 | $74,542,000 | $27,692,000 | $74,717,000 |
| Net Common Stock Issuance | $104,748,000 | $64,514,000 | $27,811,000 | $74,421,000 |
| Common Stock Issuance | $104,748,000 | $64,514,000 | $27,811,000 | $74,421,000 |
| Net Other Financing Charges | - | $1,546,000 | $3,105,000 | $4,434,000 |
| Other | ||||
| Repayment Of Debt | $-311,000 | $-1,858,000 | $-3,273,000 | $-4,718,000 |
| End Cash Position | $79,398,000 | $49,898,000 | $16,657,000 | $53,888,000 |
| Beginning Cash Position | $49,898,000 | $16,657,000 | $53,888,000 | $57,466,000 |
| Changes In Cash | $29,500,000 | $33,241,000 | $-37,231,000 | $-3,578,000 |
| Proceeds From Stock Option Exercised | $9,368,000 | $10,340,000 | $49,000 | $580,000 |
| Net Issuance Payments Of Debt | $-311,000 | $-1,858,000 | $-3,273,000 | $-4,718,000 |
| Net Short Term Debt Issuance | $-311,000 | $-1,858,000 | $-3,273,000 | $-4,718,000 |
| Short Term Debt Payments | $-311,000 | $-1,858,000 | $-3,273,000 | $-4,718,000 |
| Net Investment Purchase And Sale | $0 | $13,872,000 | $13,170,000 | $12,433,000 |
| Sale Of Investment | $0 | $13,872,000 | $77,388,000 | $134,022,000 |
| Change In Working Capital | $2,520,000 | $-1,441,000 | $-8,844,000 | $-614,000 |
| Change In Other Current Liabilities | $-759,000 | $295,000 | $464,000 | $0 |
| Change In Payables And Accrued Expense | $3,859,000 | $-2,062,000 | $-6,562,000 | $5,475,000 |
| Change In Accrued Expense | $1,168,000 | $730,000 | $-1,635,000 | $-3,346,000 |
| Change In Payable | $2,691,000 | $-2,792,000 | $-4,927,000 | $8,821,000 |
| Change In Account Payable | $2,691,000 | $-2,792,000 | $-4,927,000 | $8,821,000 |
| Change In Prepaid Assets | $-580,000 | $1,872,000 | $359,000 | $-1,654,000 |
| Other Non Cash Items | $124,000 | $1,744,000 | $3,147,000 | $-404,000 |
| Stock Based Compensation | $13,467,000 | $7,360,000 | $9,603,000 | $11,177,000 |
| Depreciation Amortization Depletion | $426,000 | $354,000 | $443,000 | $415,000 |
| Depreciation And Amortization | $426,000 | $354,000 | $443,000 | $415,000 |
| Depreciation | $426,000 | $354,000 | $443,000 | $415,000 |
| Gain Loss On Investment Securities | $4,782,000 | $56,573,000 | $66,000 | - |
| Net Income From Continuing Operations | $-105,624,000 | $-119,763,000 | $-82,508,000 | $-105,584,000 |
| Purchase Of Investment | - | $0 | $-64,218,000 | $-121,589,000 |
| Change In Other Working Capital | - | $-1,546,000 | $-3,105,000 | $-4,435,000 |
| Amortization Of Securities | - | - | $3,589,000 | $4,282,000 |
Fetched: 2026-02-02